Valuation: CEL-SCI Corporation

Market Cap 28.66M 24.59M 22.96M 21.06M 39.61M 2.74B 40.26M 271M 106M 1.37B 108M 105M 4.54B P/E 2026 *
-0.53x
P/E 2027 * -0.26x
Enterprise Value 23.11M 19.82M 18.51M 16.98M 31.93M 2.21B 32.46M 218M 85.52M 1.11B 86.77M 84.88M 3.66B EV / Sales 2026 *
-
EV / Sales 2027 * 3.91x
Free-Float
93.73%
Yield 2026 *
-
Yield 2027 * -
1 day+3.14%
1 week+10.81%
Current month+41.38%
1 month+40.17%
3 months+3.14%
6 months-66.12%
Current year-68.82%
1 week 1.45
Extreme 1.45
1.69
1 month 1.14
Extreme 1.14
1.75
Current year 0.89
Extreme 0.89
6.75
1 year 0.89
Extreme 0.89
13.48
3 years 0.89
Extreme 0.89
96.91
5 years 0.89
Extreme 0.89
387.04
10 years 0.89
Extreme 0.89
1,227.42
Manager TitleAgeSince
Chief Executive Officer 67 31/12/1994
Director of Finance/CFO 75 12/11/2024
Chief Tech/Sci/R&D Officer - 30/04/2024
Director TitleAgeSince
Director/Board Member 67 31/12/1994
Director/Board Member 73 21/06/2015
Chairman 69 07/07/2024
Date Insider Type Main position Quantity % Market Cap.
14/08/26 Free

Chief Financial Officer

225,000 1.2874%
14/08/26 Free

Director

110,000 0.6294%
14/08/26 Free

General Counsel

80,000 0.4577%
Change 5-day change 1-year change 3-year change Capi.($)
+3.14%+10.81%-80.64%-95.63% 28.66M
-1.90%+3.12%+81.70%+110.88% 72.21B
+0.93%+17.42%+57.28%+94.21% 63.98B
+1.71%-1.22%+2.71%+501.29% 28.53B
+3.51%+8.53%+62.05%+24.67% 25.07B
+21.96%+21.98%+1.54%+2.50% 28.42B
+0.98%+7.36%+40.85%-12.87% 20.04B
0.00%-2.78%+247.46%+423.83% 18.19B
+1.24%+0.76%+22.85%+522.94% 15.96B
+2.39%+7.96%+44.96%+157.77% 13.48B
Average +3.39%+6.23%+48.08%+172.96% 28.59B
Weighted average by Cap. +2.64%+6.69%+61.31%+164.21%

Financials

2026 *2027 *
Net sales - 5.97M 5.12M 4.78M 4.39M 8.25M 571M 8.39M 56.44M 22.1M 286M 22.42M 21.94M 947M
Net income -25.08M -21.52M -20.09M -18.43M -34.66M -2.4B -35.24M -237M -92.84M -1.2B -94.19M -92.14M -3.98B -29.51M -25.32M -23.64M -21.69M -40.79M -2.82B -41.46M -279M -109M -1.41B -111M -108M -4.68B
Net Debt -5.55M -4.76M -4.45M -4.08M -7.68M -531M -7.8M -52.49M -20.56M -266M -20.85M -20.4M -880M -5.34M -4.58M -4.28M -3.92M -7.38M -510M -7.5M -50.46M -19.76M -256M -20.05M -19.61M -846M
Logo CEL-SCI Corporation
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Employees
44
Date Price Change Volume
19/08/26 US$1.640 +3.14% 184,790
18/08/26 US$1.590 +2.58% 228,788
17/08/26 US$1.550 +0.65% 129,424
14/08/26 US$1.540 +3.36% 218,400
13/08/26 US$1.490 +0.68% 57,197
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.640USD
Average target price
12.50USD
Spread / Average Target
+662.20%

Annual profits - Rate of surprise